Searched for
DRUG PATENT EXPIRY
India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Profit on paper, loss in reality: How a routine accounting tool is used to deceive and take investors for a rideAmortisation is a number most investors skip, but it can shape reported profit. On the surface, it looks routine: A company spreads the cos...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Stocks in news: SBI, Titan, Hyundai, BSE, Torrent Pharma, Axis BankIndian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...
- Banking, financials remain strong play despite near-term volatility: Sunil SubramaniamCrude oil prices and UAE's role in OPEC+ are influencing Indian markets. Experts suggest oil prices may fall in the medium term, easing con...
- Weight-loss drug craze for Ozempic, Mounjaro surges in India amid safety concernsIn India, appetite for weight-loss drugs is on the rise, with consumers increasingly turning to injectables such as Mounjaro and Ozempic fo...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipelineGilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...
- Novo Nordisk plans to cut price of Ozempic as generics hit marketNovo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmake...
- Mankind Pharma targets early Semaglutide launchMankind Pharma is set to enter India's semaglutide market soon. The drug's patent expires this month, opening doors for new players. Mankin...
- Pharma MNCs seek relief from price control for patented drugsThe Organisation of Pharmaceutical Producers of India (OPPI) is requesting exemptions for patented and orphan drugs from government price c...
- Mega diabetes drug to be cheaper soonWith Novartis losing patent protection for Vildagliptin in December, the cost of therapy is expected to reduce by over 50%.
- Drug patents expiry to give generic pharma market shot in armThe patent expiry of several major 'blockbuster' drugs, coupled with other factors, will fuel growth of global generic pharmaceuticals mark...
- Patent expiry to open huge opportunity for Indian pharmaPatent expiry will be a major avenue of growth for the Indian pharmaceutical industry as products worth $235 billion are going off patent w...
- US court to hear Glenmark's patent dispute on Aug 19Glenmark Pharmaceuticals’ patent challenge against Schering Plough’s cholesterol-lowering drug Zetia will come up for hearing in the US dis...
Load More
